Dyslipidemia treatment among patients with coronary artery disease in a managed care organization

American Journal of Health-System Pharmacy

Volumn 61, Issue 10, 2004, Pages 1032-1038

  Lewis, Barbara Edelman ^a,b   McDonough, Kenneth ^a  

^a ASTRAZENECA   (United Kingdom)

^b AstraZeneca LP ^*  (United States)

Author keywords

Antilipemic agents; Coronary disease; Guidelines; Hyperlipidemia; Managed care organizations; National Cholesterol Education Program; Physicians; Prescribing

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; MEDICAL INFORMATICS; MEDICAL RECORD; ORGANIZATION; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; MEDICAL AUDIT; ORGANIZATION AND MANAGEMENT; RETROSPECTIVE STUDY; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; HYPERLIPIDEMIAS; MANAGED CARE PROGRAMS; MEDICAL AUDIT; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 3543093848     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.10.1032     Document Type: Article

References (20)

1. Heart disease and stroke statistics - 2003 update. Dallas, TX: American Heart Association; 2003.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344:1383-9.
3. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol And Recurrent Events (CARE) trial. Ann Intern Med. 1998; 129:681-9.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339:1349-57.
5. Hunt D, Young P, Simes J et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001; 134:931-40.
6. Stein EA. Aggressive treatment of dyslipidemia: a review of supporting evidence. Cleve Clin J Med. 2001; 68:130-42.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001; 285:2486-97.
8. Jacobson TA, Griffiths GG, Varas C et al. Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. Arch Intern Med. 2000; 160:1361-9.
9. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003; 361:2005-16.
10. Sever PS, Cahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361:1149-58.
11. Abookire SA, Karson AS, Fiskio J et al. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001; 161:53-8.
12. Banks T, Ali N. Coronary care physician 1994-2000 adherence to 1993 National Cholesterol Education Program diet and lipid recommendations. J Natl Med Assoc. 2001; 93:87-91.
13. Durrington P. The human and economic costs of undertreatment with statins. Int J Clin Pract. 2002; 56:357-68.
14. Lim SS, Vos T, Peeters A et al. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria. Med J Aust. 2001; 175:459-64.
15. Forthman MT, Dove HG, Wooster LD. Episode treatment groups (ETGs): a patient classification system for measuring outcomes performance by episode of illness. Top Health Inform Manage. 2000; 21:51-61.
16. Hippisley-Cox J, Cater R, Pringle M et al. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ. 2003; 326:689-93.
17. Gaw A. A new reality: achieving cholesterol-lowering goals in clinical practice. Atherosclerosis Suppl 2002; 2:5-11.
18. Frolkis JP, Pearce GL, Nambi V et al. Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice. Am J Med. 2002; 113:625-9.
19. Benner JS, Glynn RJ, Mogun H et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288:455-61.
20. Wang TJ, Stafford RS, Ausiello JC et al. Randomized clinical trials and recent patterns in the use of statins. Am Heart J. 2001; 141:957-63.